Expert Review on the Use of Methylphenidate in Children and Adult With Epilepsy and Attention Deficit Hyperactivity Disorder.
Revista de neurologia · 2026
Abstract originale
Attention deficit hyperactivity disorder (ADHD) is a comorbidity affecting 12%-29% of individuals with epilepsy, significantly impacting learning, psychosocial development, behaviour, and quality of life. Moreover, ADHD and epilepsy share a bidirectional relationship. Although methylphenidate has been proven effective in alleviating ADHD symptoms, its use remains limited in individuals with epilepsy due to outdated concerns-dating back over 20 years-that psychostimulants could increase seizure frequency. This manuscript presents a narrative review of the scientific literature published between January 2000 and May 2026 regarding the use of methylphenidate in patients with epilepsy and ADHD. Based on the available evidence, a panel of paediatric neurologists from five Spanish tertiary hospitals with expertise in epilepsy and neurodevelopmental disorders reached an expert consensus and developed a series of practical recommendations for the assessment and management of these patients. This expert group issued several recommendations, including the proactive screening of ADHD symptoms in all children and adults with epilepsy from the onset of the condition. Current evidence has not consistently demonstrated an increased seizure risk associated with methylphenidate in patients with epilepsy, although available data remain limited for some epilepsy subgroups. Furthermore, undertreatment of ADHD is associated with poorer patient outcomes. Methylphenidate may be considered in children and adults with epilepsy when clinically indicated, following optimization of epilepsy management, associated comorbidities, and behavioural and psychosocial interventions. Treatment decisions should be individualized, particularly in patients with active epilepsy, drug-resistant epilepsy, recent seizure worsening, or developmental and epileptic encephalopathies.
Parole chiave
Leggi il testo integrale originale
Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.
Expert Review on the Use of Methylphenidate in Children and Adult With Epilepsy and Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder (ADHD) is a comorbidity affecting 12%–29% of individuals with epilepsy, significantly impacting learning, psychosocial development, behaviour, and quality of life. Moreover, ADHD and epilepsy share a bidirectional relationship. Although methylphenidate has been proven effective in alleviating ADHD symptoms, its use remains limited in individuals with epilepsy due to outdated concerns—dating back over 20 years—that psychostimulants could increase seizure frequency. This manuscript presents a narrative review of the scientific literature published between January 2000 and May 2026 regarding the use of methylphenidate in patients with epilepsy and ADHD. Based on the available evidence, a panel of paediatric neurologists from five Spanish tertiary hospitals with expertise in epilepsy and neurodevelopmental disorders reached an expert consensus and developed a series of practical recommendations for the assessment and management of these patients. This expert group issued several recommendations, including the proactive screening of ADHD symptoms in all children and adults with epilepsy from the onset of the condition. Current evidence has not consistently demonstrated an increased seizure risk associated with methylphenidate in patients with epilepsy, although available data remain limited for some epilepsy subgroups. Furthermore, undertreatment of ADHD is associated with poorer patient outcomes. Methylphenidate may be considered in children and adults with epilepsy when clinically indicated, following optimization of epilepsy management, associated comorbidities, and behavioural and psychosocial interventions. Treatment decisions should be individualized, particularly in patients with active epilepsy, drug-resistant epilepsy, recent seizure worsening, or developmental and epileptic encephalopathies.
1. Introduction
Attention deficit hyperactivity disorder (ADHD) is currently regarded as one of
the most common neurodevelopmental disorders, and is a common presenting
complaint in paediatric neurology practice. It is a neurobiological disorder
which is characterised by difficulties in regulating activity levels
(hyperactivity), inhibiting thoughts and/or behaviours (impulsivity) and
maintaining attention while engaging in tasks that require cognitive effort
(inattention) [1,2,3,4,5]. Its prevalence worldwide is estimated at around 5–7% in
children, and 1–5% in the adult population [6,7]; and at 6.8% in Spain’s
paediatric population [8].
Meanwhile, epilepsy is defined as a brain disorder characterised recurring
epileptic seizures, which is associated with neurobiological,
cognitive-behavioural and social consequences, and is a very common presenting
complaint in neuropaediatrics. Its rate of prevalence in Europe is 0.7% of the
population, affecting around six million people (between 300,000 and 400,000 in
Spain), with 400,000 new cases each year and an incidence worldwide of 61.44 per
100,000 people per year [9]. Children with epilepsy have a high prevalence of
psychiatric and neurological comorbidities (including learning difficulties, mood
disorders, anxiety, autism spectrum disorder (ASD) and cognitive impairments).
Among all these conditions, ADHD is the most common comorbidity in children with
epilepsy [10].
According to several recent meta-analyses, ADHD prior to the onset of epilepsy
is common in children, with an estimated prevalence of 12%–39%, which is a risk
three to five times higher than in the population without epilepsy [11,12,13,14,15,16,17,18]. The
prevalence of ADHD is even higher in children with drug-resistant epilepsy,
accounting for as many as 70% of cases [19]. However, this relationship is
two-way [20], meaning that epilepsy may also be present in 3.4% of people with
ADHD (2.53–4.21%) [11,21]. Estimates suggest that as many as 20–50% of
children with epilepsy have subclinical symptoms of ADHD [22]. This very common
association is due to the fact that both epilepsy and ADHD share common
neurobiological mechanisms, including aberrant frontocerebellar and
frontostriatal neural networks, alterations in ion channel function, and
imbalances in neurotransmission [23] related to genetic factors and to the
epileptiform activity itself, and epigenetic factors, which affect neuronal
plasticity and regeneration and which may contribute to both the neuronal
hyperexcitability typical of epilepsy, and to the attentional and executive
function impairments observed in ADHD [11,18]. Some specific genetic
neurodevelopmental disorders are associated with a high prevalence of both
conditions. These include dystrophinopathies, in which higher prevalences of both
epilepsy and symptoms of ADHD and other cognitive and behavioural disorders have
been reported, as well as Noonan syndrome and other RASopathies, in which
alterations in the signalling pathways involved in brain development may
contribute to the onset of neurodevelopmental disorders and epilepsy [24].
While there does not appear to be any significant difference between the
characteristics of ADHD in children with epilepsy and in the population without
epilepsy [25], some authors report a higher proportion of inattentive ADHD in
cases with comorbid epilepsy [26,27]. Furthermore, while ADHD predominantly
affects boys rather than girls, with a ratio of between 2:4 and 4:1 (depending on
whether the studies are clinical or observational), this gender difference has
not been reported in children with epilepsy [28,29,30].
Rationale for the Development of Expert Recommendations
As well as being the most frequently reported comorbidity in children with
epilepsy, ADHD has a negative impact on various aspects of an individual’s life,
ranging from their learning and academic performance to areas related to social
cognition, executive functions, mood and anxiety. This is one of the most
important factors contributing to a poorer quality of life for both children with
epilepsy and their relatives [31,32]. Furthermore, people with epilepsy often
experience symptoms of inattention, motor restlessness and impulsivity that
persist into adulthood, with an estimated 15–18% of adults with the condition
continuing to experience these symptoms, and an estimated prevalence of ADHD
which is more than double that of people without epilepsy. For all these reasons,
the specific treatment of comorbid ADHD based on a holistic approach to the
management of patients with epilepsy is crucially important [33,34].
There has been a consensus for many years that the therapeutic approach for all
patients with ADHD should be multimodal; i.e., it should include a combination of
psycho-educational interventions, remedial support and educational assistance,
together with cognitive-behavioural therapy, psychoeducation, psychosocial
support in the child’s environment and pharmacological treatment from the age of
six years old onwards [35]. As regards the type of pharmacological treatment,
numerous controlled studies have demonstrated the efficacy of both
psychostimulant and non-psychostimulant drugs. However, there is currently a
consensus that central nervous system (CNS) stimulants, or psychostimulants, such
as methylphenidate and lisdexamphetamine, are the first-line treatments for ADHD.
These medicines have a larger effect size, and fewer of them are needed for
treatment than non-psychostimulants; stimulants are among the most widely used
drugs for the treatment of ADHD, due to their efficacy and safety. Within this
pharmacological group, methylphenidate is regarded as the first-line treatment
for ADHD in Spain, with an estimated efficacy of around 65%–85% [35].
Despite the importance of identifying ADHD at an early stage in patients with
epilepsy, it often remains underdiagnosed, and these patients therefore do not
receive appropriate pharmacological treatment [26]. This is partially due to
long-standing concerns about the safety of using psychostimulants in patients
with epilepsy, as it was thought that they might lower the seizure threshold and
increase related morbidity. However, recent studies have shown that
psychostimulants such as methylphenidate can be used safely, without increasing
the frequency of seizures in patients with epilepsy. Given the lack of a specific
treatment for ADHD associated with epilepsy, a review of the scientific evidence
available, with recommendations based on the evidence and expert opinion are
needed.
In order to address this issue, a group of paediatric neurologists at five
Spanish hospitals (specializing in epilepsy and neurodevelopmental disorders, and
focusing particularly on ADHD in children and adolescents), conducted a review of
the evidence published between January 2000 and May 2026, which involved an
analysis of more than 140 articles. They subsequently drew up a series of
recommendations, which are presented in Fig. 1.
This review consists of a narrative review of the scientific literature published
between January 2000 and May 2026 on the use of methylphenidate in patients with
epilepsy and ADHD, supplemented by the development of practical recommendations
based on the consensus of a group of experts. The literature search was carried
out primarily in PubMed/MEDLINE, and was supplemented by a manual review of the
references in the articles identified, and of relevant documents published by
international scientific societies. Various combinations of terms relating to
‘epilepsy’, ‘attention deficit hyperactivity disorder’, ‘ADHD’,
‘methylphenidate’, ‘stimulants’, ‘psychostimulants’, ‘children’ and ‘paediatric’
were used. This search strategy identified more than 140 relevant articles, which
were selected on the basis of their clinical and scientific relevance to the
objectives of the document, and included observational studies, clinical trials,
systematic reviews, meta-analyses, consensus documents and clinical practice
guidelines. As the aim of this review was to produce a narrative review containing
practical recommendations based on clinical experience, the methodology usually
used for a systematic review was not applied. Consequently, no formal assessment
of the risk of bias in the studies included was performed, the quality of the
evidence was not graded using standardised systems (such as Grading of Recommendations Assessment, Development and Evaluation (GRADE)), and a
quantitative meta-analysis was not conducted. The articles were selected based on
their clinical and scientific relevance, which was supplemented by the expert
judgement of the working group.
After the scientific literature identified had been reviewed, a panel of experts
was formed, consisting of paediatric neurologists from five Spanish hospitals
with experience in epilepsy and neurodevelopmental disorders. The consensus
process involved three online meetings, during which the available evidence was
reviewed and discussed. Proposals for practical recommendations were drawn up and
were discussed following this review, and they were subsequently amended and
refined in an iterative process until all the participants reached agreement. The
final recommendations reflect the consensus of the group of experts, which was
based both on the available scientific evidence and on the authors’ clinical
experience, as set out in Fig. 1.
2. Risk Factors and Comorbidities of ADHD in People With Epilepsy
There are several risk factors with statistically significant links to the
development of ADHD in patients with epilepsy and common comorbid symptoms that
can exacerbate the symptoms of ADHD. It is therefore essential to be able to
identify these factors. Cognitive disorders, a family history of ADHD and
epilepsy, refractory seizures, epileptiform abnormalities, the type of epilepsy,
anticonvulsant medications, psychiatric disorders and sleep disorders are basic
factors that must be taken into account in order to ensure that these patients
are managed appropriately.
2.1 Cognitive Disorders
The presence of an intellectual disability has been identified as an independent
risk factor for ADHD in children with epilepsy [27]. Children with epilepsy and
an intellectual disability are consequently at greater risk of also presenting
ADHD. In a study of 85 children with epilepsy, ADHD was present in 20% of
patients with normal cognitive function, compared to 59% of those with an
intellectual disability [36].
2.2 Family History of ADHD and Epilepsy
The global heritability rate of ADHD is estimated at 76% [27]. However, there is
less evidence on this issue in the population with epilepsy, although in one
small study of 16 children with ADHD and epilepsy, 50% of the mothers met the
criteria for ADHD [37]. According to a recent review of 46 studies, having a
family member with epilepsy was associated with a 2.58-fold increased risk of
developing ADHD [27].
2.3 Refractoriness and Type of Epilepsy
Although ADHD tends to be more prevalent in refractory epilepsies [38], it is
also a highly common comorbidity in self-limited epilepsies, which do not usually
require many lines of anti-seizure treatment. These include self-limited epilepsy
with centro-temporal spikes (SeLECTS), in which ADHD is usually present in more
than half of cases (estimated at 60%) [39], and childhood absence epilepsy, in
which the prevalence of ADHD ranges from 26–57% [27,40].
Whilst ADHD may be present in epilepsies affecting different brain regions, it
appears to be more common in those affecting the frontal lobe, as the prefrontal
cortex and the inferior frontal gyrus are key areas for the correct development
of executive functions [28].
2.4 Anticonvulsant Medications
Although any anticonvulsant medication with the potential to affect cognition
(particularly GABAergic drugs) should be considered a factor that may exacerbate
ADHD symptoms, the only anticonvulsant for which there is Grade A evidence that
it may worsen inattention symptoms is valproic acid, with treatment being
discontinued in up to 25% of cases [41]. Various reviews have also shown that
polypharmacy is associated with a higher probability of developing ADHD [27].
Current evidence suggests that new-generation drugs such as brivaracetam,
perampanel and cenobamate generally have a relatively neutral cognitive profile.
Furthermore, some treatments that have recently been included in the management
of some epileptic and developmental encephalopathies, such as cannabidiol and
fenfluramine, have been shown to have beneficial effects other than their
anticonvulsant properties, on aspects related to alertness, social interaction
and behaviour. However, the evidence available is still insufficient for specific
recommendations regarding its potential impact on the core symptoms of ADHD [42].
2.5 Psychiatric Disorders
Mood disorders, anxiety, conduct disorder and behavioural disorders (including
oppositional defiant disorder) are highly prevalent both in people with epilepsy
and in children with ADHD. Early identification is therefore recommended [41].
2.6 Sleep Disorders
It is estimated that up to 84% of children with epilepsy have some form of
sleep disorder, the most common of which include: insomnia (13–31%),
hypersomnia (10–47%), parasomnias (52%) and sleep apnoea syndrome (10–30%).
Likewise, 25–70% of children with ADHD experience frequent sleep disorders
[43].
2.7 Epileptiform Abnormalities
Interictal epileptiform abnormalities are common in children with epilepsy and
ADHD, with estimates suggesting that up to 51% present interictal epileptiform
abnormalities in a sleep electroencephalogram (EEG), compared with an incidence
of 1.4%–6.5% of epileptiform abnormalities in children without epilepsy [41].
However, several studies have concluded that there is currently no evidence of a
statistically significant relationship between interictal EEG changes and the
severity of attention deficit [27].
2.8 Other Factors
There is as yet no consensus, or the studies are contradictory, regarding other
factors that may be linked to the presence of comorbid ADHD, such as: an early
age of onset of epilepsy [26,44], a prolonged duration of seizures, or a high
frequency of seizures [27].
3. Diagnosis of ADHD in Children With Epilepsy
The diagnosis of ADHD is clinical, and there is currently no specific biological
marker. The most commonly used diagnostic criteria are those set out in the
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (Table 1)
[45]. Although the DSM-5 diagnostic criteria remain the clinical standard for the
diagnosis of ADHD, attentional and behavioural symptoms may also be interpreted
in dimensional and transdiagnostic neurodevelopmental models in patients with
epilepsy. This perspective recognizes the existence of shared neurobiological
mechanisms between epilepsy and ADHD, as well as partially overlapping cognitive
and behavioural profiles, which reinforces the need for a comprehensive and
tailored clinical assessment.
Table 1.
ADHD symptoms and diagnostic criteria according to the DSM-5,
divided into two main categories.
DSM-5 diagnostic criteria Description
Symptom category: 1. Often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other activities.
Inattention
At least 6 of the following symptoms (for children aged 16 or younger) or 5 or more (for adolescents aged 17 and over and adults). The symptoms must have persisted for at least 6 months and be inappropriate for the level of development. 2. Often has difficulty sustaining attention in tasks or play activities.
3. Often does not seem to listen when spoken to directly.
4. Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace.
5. Often has difficulties organizing tasks and activities.
6. Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as schoolwork or homework).
7. Often loses things necessary for tasks or activities (e.g., school assignments, pencils, books, tools, keys, documents, glasses, mobile phone, etc.).
8. Often easily distracted by extraneous stimuli.
9. Often forgetful in daily activities.
Symptom category: 1.Often fidgets with hands or feet or squirms in seat.
Hyperactivity/impulsivity 2. Often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, this may be limited to subjective feelings of restlessness).
At least 6 of the following symptoms (for children aged 16 or younger) or 5 or more (for adolescents aged 17 and over and adults). The symptoms must have persisted for at least 6 months and be inappropriate for the level of development.
3. Often has difficulty playing or engaging in leisure activities quietly.
4. Is often “on the go” or often acts as if “driven by a motor”.
5. Often talks excessively.
6. Often blurts out answers to questions before the questions have been completed.
7. Often has difficulty awaiting turn.
8. Often interrupts or intrudes on others (e.g., butts into conversations or games).
Additional Diagnostic Criteria
• Age at onset: Some of the symptoms must be present before the age of 12.
• Duration: The symptoms must have been present for at least 6 months.
• Settings: The symptoms must be present in two or more settings (e.g., at home and at school or work).
• Impact on daily life: The symptoms must interfere with social, academic or occupational functioning.
DSM-5, Diagnostic and Statistical Manual of Mental Disorders.
This diagnostic process entails both the collection of comprehensive information
from parents, carers, teachers and the patient, using a semi-structured clinical
interview designed to rule out the presence of other disorders that might provide
a better explanation for the symptoms presented, as well as a thorough physical
and neurological examination, and an appropriate neurodevelopmental assessment
(Table 2, Ref. [19,26,41,44,46,47]). This diagnosis must be performed by a
clinician with training and experience in the management of ADHD and its
comorbidities (a paediatric neurologist, psychiatrist or neuropsychologist) [35,46].
Table 2.
Specific considerations when diagnosing ADHD in people with
epilepsy.
I: Identification of comorbid conditions, including mood disorders and anxiety, sleep disorders and rational polytherapy [19,26,41,46].
II. It is essential to establish whether the ADHD symptoms were present before the onset of (comorbid) epilepsy or whether they appeared or worsened following a change in anticonvulsant medication or a worsening of the epilepsy [44].
III. In cases of seizures with different clinical features, or the acute onset or worsening of ADHD symptoms, consideration should be given to performing an EEG that includes sleep monitoring to rule out the possibility that the patient has developed epileptic encephalopathy, focusing particularly on EE-SWAS (Epileptic Encephalopathy Spike-Wave Activated in Sleep) [47].
IV. It is also sometimes necessary to distinguish between staring spells in children with predominantly inattentive ADHD and epileptic seizures (generalized absence seizures or non-motor focal seizures with partial impairment of consciousness). However, this distinction is usually possible based on the patient’s medical history, with the following factors being clinically useful: the absence of these seizures during play; if they have not been witnessed by the parents; if they can be interrupted by tactile stimuli and are not induced by hyperventilation and are more typical of a non-epileptic paroxysmal disorder; an EEG will sometimes be necessary [19,41].
Although the two conditions are closely linked, ADHD in children with epilepsy
is often underdiagnosed, as the attentional and cognitive-behavioural
difficulties experienced by this group are frequently attributed to the epilepsy,
or to the effects of anticonvulsant medication [26].
In 2018, the Comorbidities Task Force of the International League
Against Epilepsy (ILAE) recommended actively screening for ADHD symptoms from
the age of 5–6 years, every year and following a change in anticonvulsant
medication [41]. Symptoms of inattention, motor restlessness and impulsivity
should also not be taken into account within 48 hours of a seizure [41].
Various authors recommend carrying out all the appropriate specific cognitive
assessments in cases of poor academic performance In order to identify comorbid
learning disorders [19,26,41,46].
There are as yet no specific scales for identifying symptoms associated with
ADHD in people with epilepsy. In these cases, and although they are under no
circumstances a substitute for a detailed clinical assessment, a structured
interview with parents and children, information provided by teachers, and the
judgement of the clinician making the diagnosis may be helpful for diagnosis and
follow-up. The following have proven useful in this regard: the parent/teacher
version of the Child Behaviour Checklist (CBCL) from Achenbach’s
Evidence-Based Assessment System [48], the ADHD Rating Scale and the
Swanson, Nolan, Pelham-IV (SNAP-IV) questionnaire, amongst others [49].
One of the scales that has proven most useful in detecting comorbidities is the
Strengths and Difficulties Questionnaire (SDQ), which has been validated in
Spanish and demonstrates high levels of sensitivity in identifying behavioural
disorders in children aged 4–16 years, correlating with the presence of a
psychiatric diagnosis, including ADHD, in 93.6% of cases [50]. Other tools that
could be useful in a clinical setting for identifying impairments in executive
functions are the EpiTrack Junior [51] and the Behavioural Rating Inventory of
Executive Function (BRIEF) [52].
4. Treatment of ADHD in Children With Epilepsy
4.1 Non-Pharmacological Treatment
The main objectives of ADHD treatment in patients with epilepsy are to alleviate
the core symptoms that characterize the condition (inattention, hyperactivity,
impulsivity), improve the quality of life of the patient and their family, and
prevent the onset of complications or comorbidities in the medium and long term.
The therapeutic approach to patients with epilepsy and comorbid ADHD should be
similar to that adopted for patients with the same conditions but without
epilepsy (multimodal treatment, including psychoeducation, psychological and
behavioural interventions, educational support and pharmacotherapy) [35].
Comorbid disorders must be considered in people with epilepsy, as their
treatment would improve both the symptoms of ADHD and epilepsy, such as sleep
disorders and psychiatric comorbidities [53]. It is also important to consider
the importance of choosing the right anticonvulsant medication; it must involve
the optimization of a rational anticonvulsant therapy, while avoiding
anticonvulsant medication associated with significant cognitive impairment (such
as topiramate, valproic acid or GABAergic agents, such as phenobarbital and
benzodiazepines) [54].
4.2 Pharmacological Treatment of ADHD
4.2.1 Methylphenidate
Methylphenidate is a drug which acts as a stimulant of the central nervous
system. Its main mechanism of action involves increasing dopaminergic and
noradrenergic transmission in the prefrontal cortex and the striatum by
inhibiting the dopamine transporter (DAT)1 and norepinephrine transporter (NET) presynaptic transporters respectively. It also
increases the activity of the vesicular monoamine transporter (VMAT), which
transports amines (e.g., dopamine, noradrenaline, serotonin and histamine) into
the vesicles located in the presynaptic neurons, in preparation for their
subsequent release. All these effects of methylphenidate lead to higher levels of
dopamine and noradrenaline in the extracellular space. Methylphenidate is also an
agonist of the 5HT1A serotonin receptors and the α2 adrenergic receptors
[55,56]. It has been shown to increase histamine levels in the prefrontal cortex
in animal models, and this mechanism may contribute to the regulation of
attention and impulse control. However, the clinical relevance of this finding in
humans has not been fully established, and most of the available evidence comes
from preclinical studies [57].
Methylphenidate is available in Spain in various forms: immediate-release, in
modified-release capsules containing 50:50 pellets (50% immediate-release, 50%
prolonged-release) and 30:70 pellets, and in a prolonged-release form using the
methylphenidate-osmotic-release oral system (OROS)® 22:78 osmotic-release system. The effective
dose in children is usually between 0.5–1.5 mg/kg/day, but it should be adjusted
to the individual concerned, and increased gradually (Table 3).
Table 3.
Main stimulant and non-stimulant medications used to treat ADHD
in Spain (updated in March 2026).
Type of drug Generic name Trade name Formats Dosage
(Maximum dose)
Stimulant Methylphenidate (Immediate-release) Rubifen® 5, 10 and 20 mg tablets Start with 5 mg 1–2 times a day. Weekly increments of 5–10 mg.
Medicebran®
(60 mg)
Methylphenidate (50:50 modified-release) Medikinet® 5, 10, 20, 30, 40 and 50 mg capsules Start with 5 mg of MP IR once or twice a day, or 10 mg of Medikinet once a day. Weekly increments of 5–10 mg. Adults: Start with 10 mg, with weekly increments of 10 mg.
(Children: 60 mg; Adults: 80 mg)
Rubifen Prolong® 10, 20, 30, 40 and 60 mg capsules Start with 20 mg. Weekly increments of 10–20 mg.
(Children: 60 mg; Adults: 80 mg)
Methylphenidate (30:70 modified-release) Equasym® 10, 20, 30, 40 and 50 mg capsules Start with 5 mg of MP IR once or twice a day, or 10 mg of Equasym once a day. Weekly increments of 5–10 mg.
(Children: 60 mg; Adults: 80 mg)
Methylphenidate (OROS® 22:78 prolonged-release) Concerta® 18, 27, 36, 45 and 54 mg capsules Start with 18 mg. Weekly increments of 18 mg.
Rubicrono®
Atenza® (Children: 54 mg; Adolescents and adults: 72 mg)
Lisdexamfetamine (prolonged-release) Elvanse® 30, 50 and 70 mg capsules Start with 30 mg. Increments of 20 mg.
(70 mg)
Non-stimulant Atomoxetine Atamax® 10, 18, 25, 40, 60 and 80 mg capsules Children: Start with a dose of 0.5 mg/kg. Fortnightly increments up to 1.2 mg/kg/day
Atomoxetine Cinfa®
Strattera® 4 mg/mL oral solution
Atomoxetine TecniGen®
Guanfacine Intuniv® 1, 2, 3 and 4 mg tablets Start with 1 mg per day. Weekly increments of 1 mg.
(7 mg)
Clonidine Catapresan® 0.15 mg tablets Patient ≤45 kg: start with 0.05 mg/day at bedtime. Increments every 3–7 days, and administered in divided doses every 6 hours
(0.3 mg/day)
Patient >45 kg: start with 0.1 mg/day at bedtime. Increments every 3–7 days, and administered in divided doses every 6 hours
(0.4 mg/day)
The available formulations, the maximum authorized doses and the regulatory
status may vary from country to country. Physicians should consult the current
prescribing information and the relevant national regulatory authorizations
before prescribing any of these medicines.
N.B.: the doses shown are the recommendations commonly used in Spain and must be
tailored to the individual patient’s age, weight, clinical response and
tolerability. The approved indications, available formulations and maximum doses
may vary from country to country.
4.2.2 Efficacy of Methylphenidate in Patients With ADHD and
Epilepsy
Both current guidelines and recent network meta-analyses based on 190 randomised
clinical trials strongly support the use of psychostimulants as the most
effective treatment for ADHD, taking into account both pharmacological and
non-pharmacological options [35].
4.2.2.1 Evidence in the Paediatric Population
The first efficacy studies of methylphenidate in children with ADHD and epilepsy
focused on demonstrating improvements in various measurements of executive
dysfunction, particularly planning, cognitive flexibility and inhibitory control,
which is often a characteristic of children and adults with ADHD [58,59].
Several series involving 10–13 children with ADHD and epilepsy were published at
the end of the last century, and reported that methylphenidate improved various
executive functions as measured by different neuropsychological tests [60,61,62].
Improvements in ADHD symptoms have subsequently been demonstrated using rating
scales in various studies with small sample sizes, such as the retrospective
study by Socanski et al. [63] involving 14 children with ADHD and epilepsy, which
reported an 85% improvement in the core symptoms of ADHD following the
administration of methylphenidate, and the phase 1 trial by Gonzalez-Heydrich et
al. [64], which reported an improvement in the core symptoms of ADHD in the group
treated with methylphenidate-OROS® compared to the placebo group.
The efficacy of methylphenidate in the treatment of ADHD in children with
epilepsy has primarily been demonstrated in two open-label studies with large
sample sizes. The first study, by Gucuyener et al. [65], which assessed 57
children with epilepsy and 62 with electroencephalographic abnormalities, found
that methylphenidate significantly reduced ADHD symptoms on both the Conners
Scale (p
< 0.05) and the ADHD Rating Scale (p
< 0.001).
Likewise, the results of a multi-centre observational study carried out in France
by Rheims et al. [66], which included 167 children with epilepsy, of whom 46%
had active epilepsy and 26% were being treated with more than two anti-epileptic
drugs, showed that those who received methylphenidate experienced a significant
improvement in ADHD symptoms according to the ADHD Rating Scale compared with
those who did not receive psychostimulants (75% versus 42%; p
<
0.001).
4.2.2.2 Evidence in the Adult Population
Although there is less evidence in adults, the study by Adams et al. [67]
conducted an open-label methylphenidate trial after a double-blind phase involving 28 adults with ADHD
and epilepsy, with a mean age of 36.4 years and an average of 2.8 seizures per
month, which showed an improvement in the Conners Continuous Performance Test,
which assesses sustained attention in the treated group (p
< 0.002).
In short, although whether the efficacy of methylphenidate varies according to
the etiology and different epileptic syndromes is unknown, the efficacy of
methylphenidate in the paediatric population with epilepsy is estimated at
65–85% [35], a similar level to that in the non-epileptic population. However, these
results are based on heterogeneous populations, and the available evidence in
patients with drug-resistant epilepsy and epileptic and developmental
encephalopathies remains limited. The evidence in adults is more limited,
although the studies available point towards the same conclusions [66,67].
Indeed, a recent Cochrane review concluded that there was sufficient evidence
that methylphenidate was effective in people with ADHD and epilepsy [54].
Furthermore, the latest recommendations by the ILAE Comorbidities Task Force
Comorbidities Group include a level B recommendation for the use of
methylphenidate in children with epilepsy and ADHD, while atomoxetine and
amphetamines were classified as Level C and level U [41].
4.2.3 The Efficacy of Methylphenidate on Quality of Life and
Cognitive Impairments
Patients with epilepsy frequently present a range of cognitive impairments which
go beyond the executive functions and symptoms of inattention typically reported
in this population. These conditions can be improved both by optimizing seizure
control through rational polytherapy, and by managing the secondary effects of
anticonvulsant medication, as well as by cognitive stimulation and rehabilitation
[68].
Due to its multiple mechanisms of action, methylphenidate could theoretically
contribute to improved cognition and memory in patients with epilepsy. In
addition to the improvement brought about by its noradrenergic and dopaminergic
effects, which regulate activity and communication between the ventrolateral
prefrontal cortex and the hippocampal formation, methylphenidate is also thought
to increase extracellular levels of histamine, which play a key role in
alertness, memory and learning [57].
4.2.3.1 Paediatric Population
Methylphenidate is used for the overall improvement of the cognitive dysfunction
associated with conditions such as major depression and various neurodegenerative
diseases [69]. However, a narrative review concluded that whilst it may improve
some cognitive domains in people with ADHD, it may not improve other aspects,
such as distractibility and planning [70].
However, a meta-analysis examining the cognitive effects of methylphenidate in
children and adolescents with ADHD in 60 studies found statistically significant
and consistent positive effects, not only on working memory but also on other
aspects such as reaction time and response inhibition [71].
4.2.3.2 Adult Population
Various studies involving both children and adults have also shown positive
effects on memory processes, and particularly declarative and visuospatial memory
[72].
These patients’ quality of life correlates positively with their ADHD symptom
scores. Patients with epilepsy and ADHD score lower than patients with epilepsy
and without ADHD for physical well-being, self-esteem, family and social
relationships, and academic performance. Similarly, the results of a survey of
1361 adults with active epilepsy showed a poorer quality of life when ADHD
symptoms were also present [73]. In this context, treatment with methylphenidate
has been shown to improve quality of life in children and adults with ADHD and
various types of epilepsy [35,67,74].
4.2.4 Safety of Methylphenidate in Patients With Epilepsy
Although psychostimulants, and amphetamine derivatives in particular, were
initially considered potential anticonvulsant medications, based on the theory
that dopamine (DA) receptor signalling may suppress seizure activity, the properties of
methylphenidate as a CNS stimulant raised concerns amongst clinicians, given the
possibility that it might increase the risk of seizures by lowering the seizure
threshold [60]. In fact, the information in various prescribing documents states
that methylphenidate “should be used with caution in patients with epilepsy”
and US and European regulatory agencies warn that “stimulants may lower the
seizure threshold and should be discontinued if the frequency of seizures
increases”.
4.2.4.1 Safety in the Paediatric Population
This concern increased following reports of isolated cases involving children
without epilepsy, in which the beginning of methylphenidate treatment, in
combination with sertraline in many cases, was linked to the onset of seizures
[75]. Hemmer et al. [76] highlighted this potential risk of increased
epileptiform activity in a study in which serial EEGs were performed on a group
of 234 children without epilepsy, in which they concluded that methylphenidate
could trigger seizures in children without epilepsy (an incidence of 0.6%);
particularly in cases with a history of interictal epileptic activity (an
incidence of 10%). This risk has not been confirmed in two subsequent
large-scale observational studies. Neither a study carried out in Hong Kong,
which involved 29,604 children and young adults diagnosed with ADHD who were
taking methylphenidate [77], or a study carried out in the United States, in
which the population monitored amounted to more than 800,000 people, found that
treatment with methylphenidate led to an increased risk of seizures [4]. This
concern was greater in patients with epilepsy.
A single prospective study involving a small sample of 33 children with ADHD and
epilepsy, which compared the frequency of seizures between those who started
treatment with methylphenidate-OROS and those on placebo, reported an
increased risk of seizures, which was directly proportional to the dose of
methylphenidate used: 0.53 seizures/100 days in the placebo group, 1.12
seizures/100 days in those who took 36 mg, and 2.30 seizures/100 days in the 54
mg group (p
< 0.001). However, the authors pointed out that these
findings would need to be verified in further studies due to the significant
limitations of their study: the small and heterogeneous sample, and the low
baseline seizure frequency (the inclusion criterion was having had a seizure in
the previous 5 years) [64].
The main limitations of all these studies are that the sample sizes were small,
other risk factors for seizures were not analysed, and most of the authors
concluded that further studies would be needed to confirm this link between
methylphenidate and seizures, as their studies did not provide sufficient
evidence of causality [60,64,74].
Nine Class II studies and 10 Class III studies have since been published,
involving between 11 and 167 patients, which have found no evidence that
methylphenidate may cause an increase in the frequency or severity of seizures,
even in children [64,65,66,74].
4.2.4.2 Safety in the Adult Population
Park et al. [78] published a retrospective study of 105 adolescents and young
adults with epilepsy, in which they reported that the use of methylphenidate approximately 20% of participants experienced seizure aggravation. These findings were confirmed in various
subsequent studies involving adult populations [67,74,79].
4.2.4.3 Safety in Drug-Resistant Epilepsy
Most studies showed that treatment with methylphenidate did not increase the
risk of seizures in patients with refractory epilepsy. However, there are two
studies with a small sample size that suggest a degree of caution is warranted.
In the first, Koneski et al. [80] reported an increase in the frequency of
seizures at 6 months in 2 out of 24 patients, but a reduction in the severity of
seizures in the sample as a whole. Subsequently, in a similar study, Santos et
al. [81] reported that 4 out of 22 children with refractory epilepsy experienced
an increase in seizure frequency three months after starting treatment with
methylphenidate.
4.2.4.4 Safety Conclusions
A number of population-based studies have been published in recent years, which
have provided additional important information about the safety of
methylphenidate and people with epilepsy. According to the Swedish National
Prescribed Drug Register for 2006–2013, 995 paediatric patients with epilepsy
experienced a reduction in seizure frequency in the first 24 weeks following the
start of pharmacological treatment for ADHD (HR 0.73; 95% CI: 0.57–0.94) [3].
Likewise, a retrospective study in the USA (undertaken between 1999 and 2010),
which compared a group of 18,166 children with epilepsy and ADHD who had begun
treatment with stimulants with a group of 54,197 children with ADHD who were not
receiving psychostimulant treatment, found no higher rate of hospitalization
related to epileptic seizures (HR 0.95; 95% CI: 0.83–1.09 and HR 0.99; 95% CI:
0.85–1.15) [1]. Furthermore, observational studies found that the dose of
methylphenidate or the etiology was associated with an increased risk of
epileptic seizures. As a result, both the latest Cochrane reviews and the
recommendations of the ILAE Comorbidities Task Force consider methylphenidate to
be safe, with a level B recommendation [41,54].
The evidence currently available does not permit firm conclusions to be drawn
about the possible differences in risk depending on the epilepsy syndrome,
etiology or the degree of seizure control. Although methylphenidate appears to be
safe in most patients with epilepsy, closer and more tailored monitoring is
recommended in those with drug-resistant epilepsy, a recent worsening of
seizures, or epileptic and developmental encephalopathies. In these patients, the
use of methylphenidate must be tailored to the individual following a careful
assessment of the benefit-risk balance and close clinical monitoring.
Given that most patients with epilepsy experience spontaneous fluctuations in
their seizure frequency, the onset of a worsening of symptoms following the start
of methylphenidate treatment does not necessarily imply a causal relationship.
Other potentially contributory factors must be ruled out before attributing this
deterioration to the drug. The authors propose a management algorithm for cases
in which the deterioration of symptoms is suspected to be due to methylphenidate
(Fig. 2).
Other potentially relevant adverse effects must be taken into account when
assessing the safety of methylphenidate in patients with epilepsy. These include
a loss of appetite, weight loss, insomnia and other sleep disorders. The latter
is particularly important in patients with epilepsy, as sleep deprivation can
increase the likelihood of seizures. Methylphenidate has a relatively low
potential for clinically relevant pharmacokinetic interactions with most
anti-seizure medicines. However, due to the frequent polytherapy in patients with
epilepsy, tailored monitoring is recommended following the beginning or
modification of treatment.
5. Limitations
This review has a number of limitations that should be taken into account when
interpreting its recommendations. First, it is a narrative review of the
literature rather than a systematic review, and although an extensive search was
carried out for the available scientific evidence, no formal methodology for the
selection and evaluation of studies based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria was followed. The
proposed recommendations should therefore be interpreted as practical guidance
based on the best available scientific evidence and the consensus of the experts,
rather than as recommendations based on a systematic review with a formal
assessment of the quality of the evidence.
Second, the proposed recommendations are based on both published evidence and
the consensus of experts. Although the panel consisted of paediatric neurologists
from five Spanish hospitals with extensive experience in epilepsy and
neurodevelopmental disorders, neither a formal Delphi methodology nor a
structured voting system was used to quantify the level of consensus reached.
The quality of the available evidence also remains limited. Most of the
published studies on the use of methylphenidate in patients with epilepsy and
ADHD are observational, retrospective or have small sample sizes. There have been
few randomised controlled clinical trials specifically designed to assess the
efficacy and safety of this treatment in this population. Furthermore, the
available evidence does not offer firm conclusions regarding possible differences
in safety based on epileptic syndrome, etiology or the degree of seizure control.
Another major limitation is the heterogeneity of the patients included in the
studies available, encompassing different ages, types of epilepsy, etiologies,
degrees of seizure control and concomitant anti-seizure treatments, making it
difficult to extrapolate the results to specific subgroups of patients.
Finally, although data from both paediatric and adult populations have been
included to provide a more comprehensive overview of the available evidence, most
of the studies involved children and adolescents. Consequently, some
recommendations applicable to adults are based on a smaller body of evidence, and
should be interpreted with caution until specific studies of higher
methodological quality become available.
6. Recommendations of the Group of Experts and Conclusion
Despite long-standing concerns about the safety of stimulant medication in
patients with epilepsy, evidence of an increased risk of seizures associated with
the use of ADHD medication is limited and based mainly on case series reports,
while large cohorts and population-based registries suggest that methylphenidate
does not increase the incidence of seizures, but may even reduce the risk of them
occurring [41,54].
As ADHD has a significant adverse impact on the academic, social and cognitive
functioning of patients with epilepsy and their families, its treatment is of
crucial importance.
The authors of this review acknowledge that randomized, placebo-controlled
trials are needed to enhance the evidence available regarding the efficacy and
particularly the safety of methylphenidate in people with epilepsy and ADHD [53].
The available evidence is particularly strong in the paediatric population,
whilst data for adults are more limited, but generally consistent regarding the
efficacy and safety of methylphenidate.
Despite the need to improve the evidence available regarding the pharmacological
treatment of ADHD in children and adults with epilepsy, any comprehensive
management of patients with epilepsy must include the treatment of their comorbid
conditions, including ADHD. While methylphenidate is a drug that has been shown
to be effective in treating ADHD symptoms in children and adults with epilepsy
(to a similar extent as in the population without epilepsy), the available
evidence does not suggest that the majority of patients with epilepsy treated
with methylphenidate experience a clinically relevant increase in the frequency
of epileptic seizures, although an increased risk in certain populations for
which the available evidence remains limited cannot be entirely ruled out.
For all these reasons, this group of experts believes that methylphenidate may
be a therapeutic option for children and adults with epilepsy and ADHD when
clinically indicated, following an appropriate diagnostic assessment and the
optimization of treatment for epilepsy, its comorbidities and non-pharmacological
interventions. The decision to start treatment must be made on a case-by-case
basis, particularly in patients with active epilepsy, drug-resistant epilepsy, a
recent worsening of seizures, or epileptic and developmental encephalopathies
(Fig. 1).
Come citare questo studio
Víctor Soto Insuga, María Eugenia Russi, Elena González Alguacil, Javier López Pisón, Sergio Aguilera Albesa, Ignacio Málaga Dieguez, Carmen Fons. (2026). Expert Review on the Use of Methylphenidate in Children and Adult With Epilepsy and Attention Deficit Hyperactivity Disorder.. Revista de neurologia. DOI: 10.31083/rn52291
Consulta la pubblicazione originale ↗